Related Experiment Video
Updated: Jul 1, 2025
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. pbose@mdanderson.org.
Purpose Of Review:
Summarize best practices for management of patients with early myelofibrosis (MF).
Recent Findings:
Myelofibrosis is a progressive myeloproliferative neoplasm (MPN) that generally produces burdensome symptoms and ultimately leads to worse overall survival than that observed in healthy controls or patients with other MPNs. Several Janus kinase inhibitors and various interferon formulations are now available for treatment of MF, with ruxolitinib notable for extending overall survival in addition to improving MF signs and symptoms. The chronic nature of the disease can lead some patients to avoid immediate treatment in favor of a watch-and-wait approach. This review summarizes the patient management approach taken in my practice, providing guidance and a discussion of best practices with an emphasis on the importance and clinical benefits of active treatment in early MF. In particular, a case is made to consider treatment with ruxolitinib for patients with intermediate-1 risk disease and to minimize delay between diagnosis and treatment initiation for patients with intermediate or high-risk disease.
Insights
Early myelofibrosis (MF) management should prioritize active treatment over watchful waiting. Ruxolitinib is recommended for intermediate-1 risk MF, emphasizing prompt initiation of therapy for better outcomes.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Myelofibrosis (MF) is a progressive myeloproliferative neoplasm (MPN) associated with significant symptoms and reduced survival.
- Current treatment options include Janus kinase inhibitors and interferon formulations.
- A 'watch-and-wait' approach is sometimes adopted due to the chronic nature of MF.
Purpose of the Study:
- To summarize best practices for managing patients with early-stage myelofibrosis.
- To emphasize the importance and clinical benefits of active treatment in early MF.
- To provide guidance on patient management strategies.
Main Methods:
- Review of current literature and clinical practice guidelines for myelofibrosis management.
- Discussion of therapeutic options, including ruxolitinib and interferon formulations.
- Analysis of treatment initiation timing and risk stratification.
Main Results:
- Ruxolitinib has demonstrated efficacy in improving MF signs, symptoms, and overall survival.
- Active treatment, rather than a 'watch-and-wait' approach, is advocated for early MF.
- Consideration of ruxolitinib for intermediate-1 risk MF is recommended.
Conclusions:
- Prompt initiation of treatment for early myelofibrosis is crucial for improving patient outcomes.
- Ruxolitinib is a key therapeutic option, particularly for intermediate-risk disease.
- Personalized management strategies incorporating risk stratification and timely intervention are essential.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
